A prospective, randomised, double-blind, parallel-group, dose-response trial was conducted to investigate the antiproteinuric effect of candesartan cilexetil, the angiotensin II type 1 receptor blocker, in patients with chronic glomerulonephritis. Patients (n=280) were treated for 12 weeks with candesartan cilexetil 2, 4, or 8 mg given orally once-daily (o.d.). The improvement in urinary protein excretion observed at the end of the treatment period was 15.9% in the 2 mg group, 25.6% in the 4 mg group, and 34.6% in the 8 mg group, respectively, showing a clear dose-response (2 mg <4 mg <8 mg; p=0.003). The mean reduction in urinary protein excretion was 11.3% in the 2 mg group, 26.3% in the 4 mg group, and 26.0% in the 8 mg group, showing a doseresponse pattern, in that the effect of 4 mg and 8 mg was greater than that of 2 mg (2 mg <4 mg ≈8 mg; p=0.010). As the observed reduction in urinary protein excretion failed to correlate with changes in mean blood pressure, it could not be attributed to the antihypertensive effect of the study drug alone. This suggests that candesartan cilexetil, 4-8 mg o.d., has antiproteinuric effects in patients with chronic glomerulonephritis.
Introduction
In Japan, chronic glomerulonephritis and diabetic nephropathy are the primary renal disorders leading to the need for dialysis. In recent years, particularly in Europe and the United States, angiotensin-converting enzyme (ACE) inhibitors have become widely known for their renoprotective effects in patients with chronic glomerulonephritis and diabetic nephropathy. [1] [2] [3] [4] Findings from preclinical trials have associated the mechanism of action of ACE inhibitors (ACE-I) with reduction in intraglomerular pressure and inhibition of extracellular matrix proliferation, resulting from the blocking of angiotensin II (Ang II) synthesis and suppression of the renin-angiotensin system (RAS). It can thus be expected that Ang II type 1 (AT 1 ) receptor blockers (ARB), which suppress the RAS by preventing the action of Ang II at the receptor level, should also provide similar renoprotective effects in patients with chronic glomerulonephritis and diabetic nephropathy.
Candesartan cilexetil, a non-peptide ARB, is currently in wide use around the world as an oral antihypertensive agent.The usual therapeutic dose in Japan is 4-8 mg daily. 5 After oral administration, candesartan cilexetil is de-esterified to the active metabolite, candesartan, 6, 7 which is primarily excreted through the bile and faeces. This means that there is no drug accumulation as a result of delayed drug excretion in patients with impaired renal function, 8 simplifying the regulation of dosage and method of administration. In comparison with ACE-Is, ARBs can also act as antagonists against Ang II formed by non-ACE pathways, such as chymase. 9 An additional advantage is that, unlike ACE-Is, ARBs do not affect bradykinin metabolism, which means that these drugs are much less often associated with the development of dry cough as an adverse reaction. 5 The present study was conducted as a prospective, randomised, double-blind, parallelgroup, dose-response trial to study the antiproteinuric effects of candesartan cilexetil in patients with chronic glomerulonephritis. Subjects were patients with chronic glomerulonephritis with a diagnosis of primary renal parenchyma disease, confirmed by kidney biopsy, who had urinary protein excretion of 0.5-5.0 g/day during the observation period. Patients were treated for 12 weeks with candesartan cilexetil 2, 4, or 8 mg once-daily (o.d.). The primary endpoint was the effect on urinary protein excretion as assessed by 24-hour urine specimens.
Materials and methods Patients
The study was conducted between July 1996 and January 1998 at 52 institutions in Japan, in accordance with the Declaration of Helsinki and its amendments, and the Japanese Good Clinical Practice (GCP). The study protocol was approved by the institutional review boards of all participating institutions, and written informed consent was obtained from all participating patients.The study was directed at patients with chronic glomerulonephritis who met the criteria of the Specified Diseases Study Group of the Ministry of Health and Welfare (1974): a total duration of abnormal urinary findings (proteinuria, cylindruria, and/or haematuria) for at least one year after the onset of acute nephritis. Furthermore, the diagnosis of primary renal parenchymal disease had to be confirmed in these patients by renal biopsy. Eligibility criteria included patients with urinary protein levels of 0.5-5.0 g/day in two consecutive 24-hour urine samples taken after discontinuation of ACE-I for at least two weeks; patients with a serum creatinine concentration of 2.5 mg/dL (220 µmol/L) or less, and outpatients aged 20 years or older. Patients were excluded if they had any of the following conditions: diabetic nephropathy, diastolic blood pressure (DBP) of 120 mmHg or greater, use of two or more antihypertensive drugs, dose titration of steroids or immunosuppressive agents, and safety concerns. Patients who had previously taken candesartan cilexetil were also excluded.
Study design
The eligibility of patients selected during the screening period was assessed at the end of the 4week observation period ( Figure 1 ). Patients who met the inclusion/exclusion criteria were randomly assigned to each treatment group: candesartan cilexetil 2 mg, 4 mg, or 8 mg o.d.. Patients were scheduled to take the study medication once a day after breakfast for 12 weeks. Treatment was discontinued if patients developed excessive hypotension, exacerbation of chronic glomerulonephritis, or clinically significant adverse events. A physical examination, measurement of blood pressure (BP) and heart rate, and laboratory tests (blood and urine analyses) were performed every four weeks. One day before each visit, patients were asked to collect their urine for 24 hours. Concomitant use of other ARBs and ACE-Is was prohibited during the study. If patients had been taking these drugs prior to enrolment, they were required to undergo a drug wash-out period of at least two weeks before entering the screening period.The dose of any other types of prescription antihypertensive drugs (e.g. calcium antagonists, β-blockers, diuretics), steroids, antiplatelet agents, immunosuppressants, vasodilators, or nonsteroidal anti-inflammatory drugs (NSAIDs), were not permitted to be changed during the study. Major changes in dietary habit were also prohibited.All blood and urine analyses were performed at each institution.
Efficacy assessment
The primary endpoint was the rate of improvement in urinary protein excretion, defined as the percentage of patients who were judged as 'improved' according to the improvement criteria for urinary protein excretion. Using the rate of reduction in urinary protein (D), as calculated from a mean of urinary protein excretion measured at two time points, the first prior to the double-blind period and the second at the end of treatment, we assessed the improvement in urinary protein and assigned the following categories: 'improved' (D >50%), 'slightly improved' (25% < D <50%), 'no change' (-25% < D <25%), 'worsened' (D <-25%), and 'not assessable.' These categories were devised in accordance with the existing efficacy assessment criteria used in double-blind studies testing other drugs indicated for urinary protein reduction in renal disease. 10, 11 Endogenous creatinine clearance (Ccr) was also measured as an index of renal function.
Tolerability
All adverse events reported during the doubleblind period were assessed for causal relationship to the test drug. All treatment groups were compared for incidence of adverse events for which a causal relationship to the test drug could not be ruled out.
Statistical analysis
The full analysis set (FAS) was defined as the analysis population including all randomised patients. The efficacy analysis set (EAS) was defined as a subset of the FAS, which excluded patients who failed to satisfy major entry criteria or those who significantly deviated from the study protocol.The EAS was analysed for the primary analysis.The FAS was analysed for the secondary efficacy and safety analysis.
For analysis of the primary endpoint (improvement rate for urinary protein), the Cochran-Armitage trend test, using a score of (-1, 0, 1) which corresponds to respective logarithmic doses, was used to evaluate the dose-response relationship. As the results were statistically significant, contrast tests using scores of (-2, 1, 1) and (-1, -1, 2) were also performed to evaluate the dose-response pattern.The dose-response relationship of the secondary efficacy endpoint (reduction rate of urinary protein) was also assessed.
The Pearson chi-square test, the Kruskal-Wallis test, and one-way analysis of variance (ANOVA) were used to assess the comparability of treatment groups, with respect to demographic and baseline variables. A p value <0.2 was considered to be statistically significant. Stratified analysis was performed to adjust for predefined covariates, as well as baseline variables with imbalance among the treatment groups. 
Results

Patient backgrounds
A total of 280 patients were randomised to treatment, with 92 patients, 96 patients, and 92 patients, in the 2 mg, 4 mg, and 8 mg group, respectively. Excluding one patient in the 2 mg group, from whom consent to participate in the study was obtained before the sponsor and medical institution had contracted to perform this clinical trial, this group was considered the FAS. Patients who were ineligible or deviated from the protocol, such as those who violated the baseline urinary protein criteria, were also removed from the FAS, to leave a total of 254 patients in the EAS (83 patients, 86 patients, and 85 patients, in the 2 mg, 4 mg, and 8 mg group, respectively). Patient characteristics for this subject population are shown in Table 1 .
In the EAS, IgA nephropathy and mesangialproliferative nephritis accounted for approximately 70% of biopsy-confirmed glomerular lesions in each treatment group. Baseline urinary protein criteria were not uniformly distributed among the treatment groups (mean value: 2,039 mg/day, 1,644 mg/day, and 1,871 mg/day, in the 2 mg, 4 mg, and 8 mg group, respectively) (one-way ANOVA, p=0.089). Serum creatinine and endogenous CCr PAPER appeared to be uniformly distributed, although an uneven distribution in serum potassium was noted (χ 2 test, p=0.079). In all groups, the rates of hypertensive and hyperlipidaemic complications were within the 30th to 40th percentiles and the rate of concomitant antihypertensive use was in the 20th percentile. Patient characteristics not uniformly distributed among groups were assessed to determine whether they affected the primary endpoint. As will be described later, no such effects were noted. Table 2 shows the improvement in urinary protein excretion in the EAS. The rate of 'improved' findings (primary endpoint) were 15.9%, 25.6%, and 34.6%, in the 2 mg, 4 mg, and 8 mg group, respectively, with the one-sided Cochran-Armitage test PAPER indicating significant dose-dependency (Z=2.733, p=0.003). There was a significant difference between findings for the 2 mg and 8 mg groups (two-sided 95% confidence interval, 4.3%-33.2%). The rate of 'slightly improved' or 'improved' was 52.4%, 61.0%, and 62.8%, in the 2 mg, 4 mg, and 8 mg group, respectively, with nearly identical findings in the 4 mg and 8 mg groups. Findings were evaluated as 'worsened' in 14.6%, 6.1%, and 11.5%, of patients in the 2 mg, 4 mg, and 8 mg group, respectively, with no consistent trend noted.
Improvement in urinary protein excretion
Results were nearly identical to those described earlier when the FAS was taken as the subject population for analysis, and also when findings for improvement were analysed by using urinary protein/creatinine ratio to correct urinary protein values for creatinine in the urine. Table 3 shows improvement in urinary protein excretion, stratified for biopsy-confirmed glomerular lesion type (IgA nephropathy, mesangial-proliferative nephritis) and for baseline serum creatinine. Results for all stratified subgroups showed dose dependence in the rate of 'improved' findings, similar to that observed in the EAS. Figure 2 shows the rate of change in urinary protein excretion over time. All treatment groups showed a significant reduction in the rate of change from baseline in week 4 of treatment or thereafter. Table 4 compares baseline and posttreatment findings for urinary protein excretion and shows the rate of reduction in urinary protein excretion. Urinary protein excretion was significantly reduced in all treatment groups, but only the 4 mg and 8 mg groups showed a significant difference in the rate of reduction in urinary protein excretion. This rate of reduction was nearly identical between the 4 mg and 8 mg groups; the contrast test, using logarithmic dose scores, showed the dose-response pattern to be 2 mg <4 mg <8 mg (F=5.56, p=0.010). Figure 3 shows the cumulative distribution of the rate of urinary protein reduction after treatment. The rate of reduction in urinary protein excretion was consistently higher in the 4 mg and 8 mg groups than in the 2 mg group for all distribution ranges, indicating more effective reduction of urinary protein excretion in both the 4 mg and 8 mg groups than in the 2 mg group. Distribution across the range of -100% to 0% (increased urinary protein excretion) was lower in the 8 mg group than in the 4 mg group. In all other ranges, distribution was identical for both of these treatment groups, except that the 8 mg group showed a higher distribution than the 4 mg group in the range of marked urinary protein reduction (more than 40%).Thus, although the 8 mg group showed a slightly larger number of patients with increased urinary protein excretion than did the 4 mg group, the higher number of patients with marked reduction in the 8 mg group showed that at least a 40% reduction in urinary protein excretion was indicative of dose dependence, which became even clearer with patients showing a reduction of 50% or greater. Figure 4 shows changes in mean blood pressure (MBP), with significant decreases from baseline in week 4 of treatment or thereafter in all groups.The correlation between MBP and the rate of change in urinary protein excretion was examined. The Pearson correlation coefficient, obtained by merging all treatment groups, was low at 0.0745, making it difficult to explain the reduction in urinary protein excretion as simply an effect of BP reduction.
Changes in urinary protein excretion
Correlation between changes in mean blood pressure and changes in urinary protein excretion
Change in endogenous creatinine clearance over time
There was no significant change in endogenous creatinine clearance between treatment groups ( Figure 5 ).
Adjustment for covariates
To estimate the improvement rate for urinary protein in each treatment group, we performed multivariate logistic regression analysis to adjust for covariates: baseline variables considered either to be confounding factors or to account for an imbalance among the treatment groups. Table 5 represents the final model obtained, suggesting that the following covariates have a relationship to the response: concomitant use of dilazep dihydrochloride (p<0.001) and steroids (p<0.001), maximum fluctuation in MBP (p=0.016) and serum potassium level (p=0.020). Adjusted improvement rates for urinary protein excretion in each treatment group were 15.0% in the 2 mg group, 27.5% in the 4 mg group, and 34.9% in the 8 mg group, respectively, which were similar to the crude results. Moreover, the doseresponse pattern, as shown by contrast tests after adjustment, was shown to be similar to that obtained before adjustment. Thus, while some baseline variables had some effect on the response, a clear dose-response relationship was shown for the primary endpoint after adjustment for those covariates.
Tolerability
No serious adverse events were noted. Adverse events were reported in 79 cases (86.8%), 84 cases (87.5%), and 80 cases (87.0%), in the 2 mg, 4 mg, and 8 mg group, respectively. Adverse events for which a causal relationship to the test drug could not be ruled out were observed in 45 cases (49.5%), 42 cases (43.8%), and 45 cases (48.9%), in the 2 mg, 4 mg, and 8 mg group, respectively. Of these events, signs and symptoms were observed in nine cases (9.9%), 11 cases (11.5%), and 10 cases (10.9%), and laboratory findings were observed in 40 cases (44.4%), 37 cases (38.5%), and 40 cases (43.5%), in the 2 mg, 4 mg, and 8 mg group, respectively. There was no statistically significant difference in the incidence of adverse events between the treatment groups. Signs and symptoms for which a causal relationship to the test drug could not be ruled out are listed in Table 6 .The most frequent signs and symptoms among all treatment groups were low BP, dizziness on standing, lightheadedness, and headache/dull headache.The incidences of laboratory findings for which a causal relationship to the test drug could not be ruled out and that were reported in more than 5% in any treatment group are listed in Table 7 . 
Discussion
Candesartan cilexetil has achieved broad acceptance internationally as an antihypertensive agent. This drug shows antihypertensive effects in a variety of animal models of hypertension, 12-14 not only reducing urinary protein in 5/6 nephrectomised hypertensive rats, but also blocking the expression of transforming growth factor-β 1 (TGFβ 1 ), inhibiting the progression of glomerulosclerosis, and suppressing fibrotic changes in the tubulointerstitium. 15 In addition, candesartan cilexetil reduces urinary protein excretion and suppresses the growth of renal tissue lesions in Wistar-Fatty Worsened urine deposit 6 2 6
All findings reported in >5% of any treatment group are listed. rats, an experimental model of Type 2 diabetes. 16, 17 The present study was done to evaluate the antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis. It was designed as a prospective, comparative, multicentre, parallel-treatment, double-blind clinical trial, in which patients were treated for 12 weeks with candesartan cilexetil at doses of 2, 4, or 8 mg o.d. The primary endpoint was the rate of improvement in urinary protein excretion, as assessed from 24-hour urine specimens.
BUN = blood urea nitrogen
The rates of improvement in urinary protein excretion after treatment with candesartan cilexetil were 15.9% in the 2 mg group (13/82 patients), 25.6% in the 4 mg group (21/82 patients), and 34.6% in the 8 mg group (27/78 patients), indicating a dose-dependent response. The 95% confidence interval at its lower limit was >0 for the difference in improvement rates between the 2 mg group and the 8 mg group, indicating that results were significantly better in the 8 mg group than in the 2 mg group. Mean rates of reduction in urinary protein excretion after treatment were 11.3%, 26.3%, and 26.0%, in the 2 mg, 4 mg, and 8 mg group, respectively, with nearly identical results obtained for the 4 mg and 8 mg groups. The discrepancy in the findings for the improvement rates (percentage of patients achieving greater than 50% reduction in urinary protein excretion) and the mean urinary protein reduction rate between the 4 mg and 8 mg groups is attributed to the fact that, compared with the 4 mg group, the 8 mg group had an equivalent or higher distribution of patients with reduction rates <40%, but a higher distribution of patients with reduction rates >40%. As these results show, the 4 mg and 8 mg doses provided more effective reduction of urinary protein excretion than did the 2 mg dose. Furthermore, a reduction in urinary protein excretion of at least 50% is more likely to be obtained with the 8 mg dose than with the 4 mg dose.
For this study, we did not establish a placebo group as a control. However, urinary protein excretion improved in a clearly dose-dependent manner after treatment with candesartan cilexetil (15.9%, 25.6%, and 34.6%, in the 2 mg, 4 mg, and 8 mg group, respectively). Clinical trials of other agents with similar protocols have shown a placebo improvement rate of only 11.1% to 17.7%, 10, 11, 18 indicating the efficacy of 4 mg and 8 mg doses of candesartan cilexetil in the treatment of chronic glomerulonephritis.
The changes in MBP at week 12 of treatment was -5.0 mmHg in the 2 mg group, -7.7 mmHg in the 4 mg group, and -9.7 mmHg in the 8 mg group; significant reductions in all groups.These findings suggest that lower systemic BP may have contributed to the reduction in urinary protein excretion attributable to candesartan cilexetil. Although logistic regression analysis indicated that the rate of improvement in urinary protein excretion was affected by maximum fluctuation in mean BP, no correlation was noted between the rate of reduction in urinary protein excretion and changes in mean BP.
The principal antiproteinuric action of candesartan cilexetil is believed to be related to a reduction of intraglomerular pressure. However, intraglomerular pressure, which is said to correlate with systemic BP in patients with glomerulonephritis, was likely not particularly high in this study population, because baseline systemic BP in this cohort was normal (approximately 130/80 mmHg). Also, there was no notable correlation between systemic BP and urinary protein reduction. In preclinical studies, 15 it is suggested that inhibition of TGF-β 1 expression, together with suppression of both glomerulosclerotic progression and fibrotic changes in the tubulointerstitium, contributes to the antiproteinuric mechanism.
The primary objective in treating renal disease is to suppress or delay aggravation of renal function. Findings from the ACE Inhibition in Progressive Renal Insufficiency (AIPRI) study of benazepril 1 and the Ramipril Efficacy In Nephropathy (REIN) study of ramipril 2 in non-diabetic patients with nephropathy indicated that prognosis was better for the treatment groups than for the placebo groups, and that these agents caused significant decreases in urinary protein excretion. The REIN study also indicated that poorer prognosis in patients was associated with higher urinary protein levels and concluded that drug effectiveness was based more on the reduction of urinary protein excretion rate than on the reduction of BP. In our study, treatment with candesartan cilexetil for 12 weeks improved urinary protein excretion dose-dependently, but did not affect endogenous creatinine clearance. A longer term clinical trial should be conducted to demonstrate more clearly the renoprotective action of candesartan cilexetil.
